Job Description:
This is a unique opportunity for a driven, highly motivated and talented Postdoctoral Scientist to join the research group of Professor Paresh Vyas at the MRC Weatherall Institute of Molecular Medicine (WIMM) to work in a University-industry collaboration to discover new lead therapeutic compounds for treatment of the most common aggressive human acute leukaemia, Acute Myeloid Leukaemia (AML). The position is fixed-term until 2 May 2019 funded by an innovative new spin-out company OxStem Oncology (www.oxstem.co.uk/product-pipeline/oncology) and will involve collaborations with Associate Professor Thomas Milne (WIMM) and the University Department of Chemistry (Professors Steve Davies and Angela Russell) The Vyas lab has a long-standing interest in the biology of normal and leukaemic stem cells. The Milne lab focuses on epigenetics of haemopoiesis and the Davies/Russell labs have made rich small molecule compound libraries. Traditionally, cancer therapies have focussed on killing tumour cells. In a highly novel approach the applicant will instead focus on identifying molecules that cure leukaemia by releasing the differentiation block in AML using high throughput screens that combine state-of-the-art cell and molecular approaches. You will hold a PhD (or near to completion) in a relevant area, with experience in FACS analysis, haematopoietic stem/progenitor cell cultures, and genome engineering (CRISPR/Cas9). Extensive bioinformatics expertise (RNA-Seq, targeted DNA-Seq, ChiP-Seq), including coding in “R” and a strong publication record are essential, as well as the ability to work independently as well as part of a team. Applications for this vacancy are to be made online. You will be required to upload a CV and supporting statement as part of your online application. The closing date for this position is 12.00 noon on Wednesday 20 July 2016. Interviews will be held week commencing 8 August 2016.
Additional Info:
[Click Here to Access the Original Job Post]
This is a unique opportunity for a driven, highly motivated and talented Postdoctoral Scientist to join the research group of Professor Paresh Vyas at the MRC Weatherall Institute of Molecular Medicine (WIMM) to work in a University-industry collaboration to discover new lead therapeutic compounds for treatment of the most common aggressive human acute leukaemia, Acute Myeloid Leukaemia (AML). The position is fixed-term until 2 May 2019 funded by an innovative new spin-out company OxStem Oncology (www.oxstem.co.uk/product-pipeline/oncology) and will involve collaborations with Associate Professor Thomas Milne (WIMM) and the University Department of Chemistry (Professors Steve Davies and Angela Russell) The Vyas lab has a long-standing interest in the biology of normal and leukaemic stem cells. The Milne lab focuses on epigenetics of haemopoiesis and the Davies/Russell labs have made rich small molecule compound libraries. Traditionally, cancer therapies have focussed on killing tumour cells. In a highly novel approach the applicant will instead focus on identifying molecules that cure leukaemia by releasing the differentiation block in AML using high throughput screens that combine state-of-the-art cell and molecular approaches. You will hold a PhD (or near to completion) in a relevant area, with experience in FACS analysis, haematopoietic stem/progenitor cell cultures, and genome engineering (CRISPR/Cas9). Extensive bioinformatics expertise (RNA-Seq, targeted DNA-Seq, ChiP-Seq), including coding in “R” and a strong publication record are essential, as well as the ability to work independently as well as part of a team. Applications for this vacancy are to be made online. You will be required to upload a CV and supporting statement as part of your online application. The closing date for this position is 12.00 noon on Wednesday 20 July 2016. Interviews will be held week commencing 8 August 2016.
Requeriments :
Skills :
Areas :
Additional Info:
[Click Here to Access the Original Job Post]